To investigate the prognostic value of plasma serotonin levels in colorectal cancer (CRC).
is well-established as a pro-mitogenic factor in a variety of cancers and has additionally been linked to increased metastasis and angiogenesis in a variety of oncogenic settings. 8, 9 In apparent agreement with this notion, a substantial body of experimental evidence obtained both in vitro and in vivo has now shown that serotonin promotes tumorigenesis in small-cell lung carcinoma, 10 prostate cancer, 11 breast cancer, 12 choriocarcinoma, 13 bladder cancer, 14 and hepatocellular cancer. 15 Nevertheless, evidence that serotonin can serve as a diagnostic or prognostic marker in human cancer is still largely absent.
In humans, approximately 90% of the total pool of serotonin is synthesized and localized to the enterochromaffin cells of the gastrointestinal mucosa, 16 suggesting that the intestine constitutes an interesting candidate for linking serotonin levels to the outcome of intestinal disease. Indeed, preclinical evidence in colon cancer xenografts has demonstrated that serotonin promotes oncological growth in this compartment. 17 Furthermore, mechanistic studies show that binding of serotonin to its cognate receptors stimulates metastasis of colon cancer cells through stimulation of β-catenin signaling. 18 As the level of β-catenin pathway activation is directly linked to the outcome of colorectal cancer (CRC), 19 it is rational to propose that serotonin levels may be linked to the outcome of oncological disease, especially in this type of cancer. Previous reports have shown that circulating serotonin levels correlate well with prognosis of bladder carcinoma, prostate adenocarcinoma, renal carcinoma, and breast cancer. 20, 21 A potential relationship between patient serotonin levels and the outcome of CRC has, however, not yet been investigated.
The above-mentioned considerations prompted us to investigate the potential correlation of circulating serotonin levels and the presence of CRC and explore the potential usefulness of such levels as a prognostic marker in this disease. The results reveal a clear relationship between plasma serotonin levels and the clinical outcome of CRC. 
| PATIENTS AND METHODS

| Study population
| Disease assessment
Preoperative demographic and clinical information analyzed for this study included patient age, gender, pre-operative serum carcinogenic embryonic antigen (CEA) level, apparent tumor size and invasion depth, lymph node metastasis, the presence distant metastasis, histological grade of the cancer, and tumor node metastasis (TNM) stage.
After the operation, patients were followed up every 3 months for 3 years and subsequently every 6 months for 2 years. Physical examinations performed included a chest X-ray, abdominal computed tomography, chest computed tomography, and colonoscopy according to routine procedures. Tumor recurrence was defined as evidence of a new lesion in the colorectal area or elsewhere outside the colorectal area, and these were classified as local recurrence and distant recurrence, respectively. Recurrence-free survival (RFS) was defined as the time between surgery and cancer recurrence. Overall survival (OS) was defined as the interval between of the surgery date and the death of the patient due to CRC or to last follow-up as appropriate.
| Blood samples and measurement of plasma serotonin
For preparation of platelet-poor plasma samples for determination of serotonin levels, we adhered strictly to the guidelines and procedures as stipulated by Brand et al. for serotonin measurements. 22 For this study, venous blood was collected from controls at entry into the present study (controls were not followed up) and for CRC patients the day prior to surgery. The blood samples were centrifuged at 200×g for 10 minutes at room temperature to obtain platelet-rich plasma and then at 4500×g for 10 minutes at 4°C to obtain plateletfree plasma. The plasma was then removed and stored at −80°C until assaying. Plasma serotonin levels were measured in duplicate using a commercial radioimmunoassay kit ( 125 I-Serotonin RIA; form DRG International, Inc., USA) according to the manufacturer's instructions.
The final value was determined by the average of two measurements.
The person conducting the assays was blinded with respect to sample identity and clinical information. values and estimations of optimal cut-off points as well as for calculating areas under the curve (AUCs). RFS and OS were assessed using Kaplan-Meier methodology, and the intergroup differences in survival time were compared using a log-rank test. Multivariate Cox's proportional hazard analysis was performed to compare and identify independent prognostic factors with respect to RFS and OS for calculating hazard ratios (HRs) and 95% confidence intervals (CIs). All significant parameters in the univariate analysis were entered into a multivariate model. All the hypotheses were constructed as two-tailed, and a P-value <.05 was considered statistically significant.
| Statistical analysis
| RESULTS
| Description of the study cohort
In this study, we included 176 therapy-naive pre-operative patients with histologically confirmed CRC, and their results were compared to a gender-and age-matched cohort of 150 BCP patients and 150
HCs ( Table 1) . As expected, the serum CEA levels of patients with P=.001; Figure 1B ). However, no significant correlation was observed between plasma serotonin level and any other clinicopathological parameter. We concluded that CRC is associated with substantially increased levels of plasma serotonin and that higher levels correspond to more severe disease.
| Recurrence and plasma serotonin levels
Eighty-six patients experienced recurrence within 5 years after surgery. Plasma serotonin was significantly higher in those patients with recurrence than in those without recurrence (13.53±4.94 and 8.91±4.30 ng/mL, respectively; P<.001, Figure 2A ). Adopting a cutoff value based on the median plasma serotonin level in the CRC group, CRC patients with a plasma serotonin level of >11.17 ng/mL were contrasted to those who displayed a plasma serotonin level of <11.17 ng/mL with respect to clinicopathological factors. Intriguingly, the 5-year recurrence rates were 61.3% (49/80) and 38.5% (37/96),
respectively, for patients with high plasma serotonin levels and those with low plasma serotonin levels, yielding a significant difference between these two groups (P=.003). ROC analyses of plasma serotonin in patients with and without recurrence are shown in Figure 3A . The optimal cut-off point as observed in this study population for plasma serotonin was 14.36 ng/mL, displaying a sensitivity and specificity of 77.3% and 81.3%, respectively, for recurrence (AUC: 0.813; 95% CI, 0.751-0.884; P<.001; Figure 3A ). We thus conclude that pre-operative plasma serotonin levels predict eventual recurrence of disease in CRC. Figure 4A shows a Kaplan-Meier analysis of RFS of our cohort following allocation of patients to the low and high plasma serotonin level groups, using the 11.17 ng/mL threshold. The median times to recurrence were 38.3 months and 48.5 months for patients with high levels of plasma serotonin and those with low plasma serotonin levels, respectively, resulting in a significant difference between the two groups (P=.001).
Finally, univariate analysis was performed in order to identify factors that were significantly associated with tumor recurrence. As depicted in Table 3 and importantly, high plasma serotonin level were independent prognostic factors of tumor recurrence (Table 3) . Hence, plasma serotonin appears to be useful as a novel prognostic marker for CRC recurrence.
| Mortality prediction and plasma serotonin levels
Seventy-two patients of our CRC patient cohort died within 5 years following surgery, allowing investigation of the power of preoperative plasma serotonin levels as a predictor of overall patient mortality. Levels of plasma serotonin were higher in non-survivors than survivors within 5 years (14.24±4.85 and 9.04±4.23 ng/mL, respectively; P<.001; Figure 2B ). Dichotomizing patients for low and high pre-operative plasma serotonin, using the 11.17 ng/mL threshold, we observed that 5-year mortality rates were 51.3% (41/80) in the high plasma serotonin group and only 32.3% (31/96) in the low plasma serotonin group, resulting in a significant difference between the two groups (P=.027). ROC analysis showed that plasma serotonin levels >15.74 ng/mL predicted 5-year mortality in CRC patients with 71.6% sensitivity and 84.8% specificity (AUC: 0.824; 95% CI: 0.762-0.879; P<.001; Figure 3B ). Hence, plasma serotonin performed well as a novel prognostic marker for mortality resulting from CRC. Figure 4B shows the Kaplan-Meier curves for OS related to plasma serotonin levels following dichotomization according to the 11.17 ng/mL threshold. The median survival times were 41.2 months and 51.1 months, respectively, for the individuals with high levels of plasma serotonin and those with low plasma serotonin levels, yielding a very significant difference between the two groups (P=.003).
In a univariate analysis of OS, the significant factors identified were the occurrence of lymph node metastasis, distant metastasis, TNM stage, serum CEA level, and plasma serotonin level. In a subsequent multivariate analysis including all the variables from the univariate analysis, positive lymph node metastasis, distant metastasis, advanced TNM stage, high serum CEA level, and high plasma serotonin level were
shown to have statistically independent prognostic value for poor OS (Table 3) . In conjunction, these data show that plasma serotonin performed well as a novel prognostic marker for 5-year mortality in CRC.
| DISCUSSION
In the classical interpretation of serotonin functionality in the body, its functionality is mainly associated with blood coagulation. Serotonin is released into the circulation and subsequently subject to reuptake by the platelet compartment. Release from the platelet compartment is the consequence of platelet activation during coagulation. Intriguingly, a link between blood coagulation and cancer progress is well-recognized, 23 and thus, investigating circulating levels of platelet secretions like serotonin appears rational. Accordingly, production of platelet activators like thrombin and/or adenosine diphosphate by tumor cells and subsequent platelet activation has been described, eg, in cervix cancer.
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This study is the first, however, to document a strict relationship between plasma serotonin and prognosis of a cancerous condition, in CRC.
Earlier studies have provided good evidence that serotonin furthers carcinogenic processes in the body by exerting a direct growth stimulatory effect on tumor cells. 14 The relationship between plasma serotonin and clinical course observed in this study suggests that similar effects are operative for CRC as well. As yet, however, the exact mechanism of tumorigenesis of serotonin in the context of CRC has not been fully elucidated. Earlier studies have shown that serotonin stimulates tumor cell proliferation and growth in preclinical models of F I G U R E 2 Scatter plots showing plasma serotonin levels in colorectal cancer patients separated by recurrence (A) and mortality (B). Black horizontal lines indicate the mean, and error bars are standard errors. Statistical analysis was carried out using the Mann-Whitney U test
Receiver operating characteristic (ROC) curves for plasma serotonin in predicting recurrence (A) and mortality (B) in colorectal cancer patients
The Kaplan-Meier survival curves for recurrence-free survival (A) and overall survival (B) in patients with colorectal cancer according to plasma serotonin levels. Plasma serotonin levels were dichotomized employing the mean overall value measured in patients (11.17 ng/mL This study extends these largely preclinical observations by showing their relevance to human disease.
In this sense, the present work relates well to clinical studies in other cancers that have provided proof that circulating serotonin levels show significant association with poor prognoses of other cancers, including urothelial carcinoma of the bladder, prostate cancer, and renal carcinoma. In these oncological manifestations, serotonin levels correlate with tumor stage, distant metastases, and life expectancy. 20 Similarly, another study showed that the plasma-free serotonin level may be used for the early detection of recurrent/metastatic breast cancer. 21 Finally, a recent study found that serotonin can be used as a highly sensitive biomarker for early diagnosis and staging of hepatocellular carcinoma. 27 Thus, a picture emerges in which elevated serotine levels, in general, are indicative of the presence of a malignant process in the body. In apparent agreement, an early, small retrospective study in patients with intestinal cancer had already shown that plasma serotonin concentrations in intestinal cancer patients were significantly higher than those in healthy individuals. 28 In conjunction with the present work, the association of circulating serotonin with colon cancer and its potential to serve as a prognostic biomarker predicting the clinical course of CRC seems compelling and should prove highly interesting whether future prospective studies employing large patient cohorts will substantiate this notion.
Particularly encouraging in this respect is that in the current study, the plasma serotonin concentration was an independent prognostic factor with respect to both OS and RFS for patients with CRC and such levels add substantially to, for instance, the predictive effect associated with advanced TNM stages. Also, in patients with advanced TNM stages, we found that the plasma serotonin level was significantly higher in patients with recurrence than in patients without recurrence.
Likewise, elevated preoperative plasma serotonin levels had independent prognostic significance for OS using either a logistic multivariate analysis and a multivariate Cox's proportional hazard analysis or ROC curve analysis. This additional predictive value of pre-operative serum serotonin levels over established indicators like TNM stages warrants, in our opinion, the conclusion that measuring such levels routinely should improve clinical management of CRC.
There are several limitations that need to be acknowledged with regard to the present work, mainly relating to the intermediate size of
the study group, its single center, and the relatively short follow-up time of 5 years. We feel, however, the results are encouraging enough for us to call for large prospective studies that should yield more definitive statements regarding the value of plasma serotonin levels in predicting clinical course in CRC. A second group of limitations relates to the fact that serotonin levels were measured only once-preoperatively-in the current study. It should prove highly interesting to study how these levels develop following surgery (eg, whether elevation of such levels would precede the detection of disease recurrence). We, thus, propose that follow-up studies based on our current work should include such serial analysis of plasma serotonin concentrations. In addition, it may be worthwhile to investigate the plasma concentrations of other platelet secretions, as to clarify the relationship to platelet activation. Hence, important questions still need to be addressed to fully understand the role of circulating serotonin in the biology of CRC and the clinical management of this disease.
| CONCLUSION
This study suggests that a high preoperative plasma serotonin level is associated with poor patient outcome and may serve as a novel prognostic biomarker for CRC.
